KCNE1: A Potential Drug Target for Various Diseases (G3753)

Target Name: KCNE1

NCBI ID: G3753

KCNE1

KCNE1: A Potential Drug Target for Various Diseases

KCNE1 (KCNE1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, lungs, and kidneys. It is a member of the unexpected family of hormone receptor superfamily, transcription factors, It is known to be involved in regulating a variety of physiological processes, such as cell proliferation, differentiation, and tumorigenesis. At the same time, KCNE1 has also been proven to be a drug target that may have important clinical value in the treatment of various neurological diseases, cardiovascular diseases, and tumors. This article will introduce in detail the structure, function, drug targets and clinical application prospects of KCNE1.

structure

KCNE1 is a 22 kDa polypeptide that contains seven transmembrane 伪-helices and three ribosome-binding sites (N-terminus). KCNE1 is mainly composed of two subunits, each subunit contains an 伪-helix and two 尾-turns. The binding between the two subunits is mediated by a 尾-coil consisting of a long amino acid sequence, resulting in a stable dimer structure.

Function

KCNE1 plays an important role in various physiological processes. First, KCNE1 is a key regulator of cell proliferation, differentiation, and tumorigenesis. Studies have shown that activation of KCNE1 can lead to changes in gene expression patterns during cell proliferation and differentiation, thereby promoting tumorigenesis. In addition, KCNE1 is also involved in regulating apoptosis, thereby having an important impact on the life cycle of cells.

In addition, KCNE1 is also involved in regulating the differentiation and function of immune cells. Research shows that KCNE1 can promote the activation and proliferation of T cells, thereby enhancing the killing effect of the immune system. At the same time, KCNE1 can also inhibit the activation and proliferation of B cells, thereby inhibiting the humoral immune response. These functions make KCNE1 a potential drug target.

drug target

As a drug target, KCNE1 has important clinical value in the treatment of various neurological diseases, cardiovascular diseases and tumors. First, KCNE1 has been shown to be a drug target for the treatment of Parkinson's disease. Some studies have shown that the expression level of KCNE1 in the brains of Parkinson's disease patients is significantly higher than that of normal people, and KCNE1 inhibitors can significantly improve the symptoms of Parkinson's disease patients. In addition, KCNE1 has also been shown to be a potential drug target for the treatment of other neurological diseases, such as Alzheimer's disease, depression, and epilepsy.

In addition to neurological diseases, KCNE1 has also been shown to be a potential drug target for the treatment of cardiovascular diseases and tumors. Studies have shown that KCNE1 can regulate the proliferation and differentiation of cardiomyocytes and participate in regulating the contraction and relaxation of myocardial fibers. In addition, KCNE1 can also regulate the growth and function of vascular endothelial cells and participate in regulating angiogenesis and permeability. These functions make KCNE1 a potential drug target for the treatment of cardiovascular diseases.

KCNE1 can also serve as a potential drug target for tumors. Studies have shown that KCNE1 can promote the proliferation and invasion of tumor cells. KCNE1 inhibitors can significantly inhibit the growth and invasion of tumor cells. These findings provide an important theoretical basis for KCNE1 as a drug target for tumor treatment.

Clinical application prospects

With the discovery and in-depth research of KCNE1 as a drug target, KCNE1 inhibitors are considered as potential drugs for the treatment of various neurological diseases, cardiovascular diseases and tumors. At present, some inhibitors targeting KCNE1 have shown good pharmacological effects in preclinical studies, such as improving neuronal survival rate, improving neuronal synaptic accessibility and inhibiting tumor cell growth.

Despite this, there are still some challenges and limitations regarding the clinical application of KCNE1. First, since KCNE1 plays an important role in a variety of physiological processes, identifying the optimal therapeutic drug target for KCNE1 remains an important challenge. Secondly, since KCNE1 is expressed in multiple tumor types, developing KCNE1 inhibitors with good therapeutic effects for tumor patients remains a challenging task.

Conclusion

As a transcription factor, KCNE1 plays an important role in cell proliferation, differentiation and tumorigenesis. At the same time, KCNE1 has also been proven to be a drug target that may have important clinical value in the treatment of various neurological diseases, cardiovascular diseases, and tumors. Currently, some inhibitors targeting KCNE1 have shown good pharmacological effects in preclinical studies, but further research is still needed to determine the best therapeutic drug targets for KCNE1 and to develop KCNE1 inhibitors with good therapeutic effects for tumor patients. Still a challenging task.

Protein Name: Potassium Voltage-gated Channel Subfamily E Regulatory Subunit 1

Functions: Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Assembled with KCNB1 modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (PubMed:19219384). Assembled with KCNQ1/KVLQT1 is proposed to form the slowly activating delayed rectifier cardiac potassium (IKs) channel. The outward current reaches its steady state only after 50 seconds. Assembled with KCNH2/HERG may modulate the rapidly activating component of the delayed rectifying potassium current in heart (IKr)

The "KCNE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets